Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with InnoCare Pharma (03696) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] - The inclusion will lead to adjustments in the eligible stocks for the Hong Kong Stock Connect, as the company meets various criteria including market capitalization, liquidity, and listing duration [1] - According to a report by CICC, InnoCare Pharma is likely to be added to the Hong Kong Stock Connect due to its compliance with the necessary standards [1] Group 2 - On February 10, InnoCare Pharma announced a strategic collaboration with Kangji Medical to develop innovative drugs powered by AI in the fields of central nervous system and autoimmune diseases [1] - The collaboration will involve at least two joint research and development projects, leveraging InnoCare's validated AI platform and Kangji's experienced R&D team [1] - InnoCare Pharma is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]
英矽智能获纳入恒生综合指数 有望成为港股通标的